ITGAM and neoplasm: Despite no significant changes of myeloid-derived suppressor cells (MDSCs) between different treatments, this immunosuppressive compartment composed of ~50% of CD11b+ cells in the tumor, posing a challenge for treatment of 4T1 TNBC (Supplementary Fig. 12d).